The Bamlanivimab+Etesevimab are anti-SARC-COVID-2 monoclonal antibodies which have received Emergency Use Authorization (EUA) from US FDA as well as conditional use approval from the MoHP, Department of Drug Administration (DDA) in Nepal.
Latest Public Health Jobs
Latest Posts
- WHO comments on United States announcement of intent to withdraw
- Procurement Improvement Guideline – 2081
- Call for Abstracts for the International Conference on Family Planning (ICFP) 2025
- Call for Abstracts & Interactive Learning Sessions: 2nd SAFETYNET Scientific Conference
- School Health and Nursing Service Directives 2081
Thanks for visiting us.
Disclaimer: The resources, documents, guidelines, and information on this blog have been collected from various sources and are intended for informational purposes only. Information published on or through this website and affiliated social media channels does not represent the intention, plan, or strategies of an organization that the initiator is associated with in a professional or personal capacity, unless explicitly indicated.
If you have any complaints, information, or suggestions about the content published on Public Health Update, please feel free to contact us at [email protected].
#StayUpdated
